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INTRODUCTION 
Primary amyloidosis (AL-type) is a rare disease that is 
characterized by deposition of proteinaceous material in 
various organs (1), with the liver and spleen being the 
major sites of involvement. However, the deterioration of 
liver function is usually mild. The clinical manifestations 
include hepatomegaly, jaundice and cholestasis (2). To date, 
there has only been a few case reports that have described 
primary amyloidosis associated with multiple myeloma and 
this resulted in subacute or acute, fulminant hepatic failure 
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(3-5). Although several case studies have reported positive 
18F-fluorodeosxy glucose (
18F-FDG) uptake in pulmonary 
amyloidosis (6, 7), to the best of our knowledge, there 
have not been any reports of the 
18F-FDG positron emission 
tomography (PET)/computed tomography (CT) findings 
in hepatic amyloidosis or primary hepatic amyloidosis 
associated with multiple myeloma. Herein, we report on 
a case of primary AL hepatic amyloidosis associated with 
multiple myeloma and this resulted in hepatic failure 
and we describe the 
18F-FDG PET/CT image findings of the 
patient. 
CASE REPORT
A 64-year-old female patient was admitted at our hospital 
with progressive jaundice and right upper quadrant pain 
for two days. The patient had a history of laparoscopic 
cholecystectomy due to gall stones two months previously. 
One month ago, a percutaneous drainage catheter had been 
inserted due to ascites. The laboratory studies performed 
at admission showed elevated total bilirubin (13.2 mg/dL; 
normal range, 0.2-1.0 mg/dL) and direct bilirubin (10.4 Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 635
FDG PET/CT in Primary Hepatic Amyloidosis
mg/dL; normal range, 0-0.3 mg/dL). The hepatic functional 
enzymes were within the normal limits.
Abdominal CT had been performed on the 11th day before 
admission at an outside hospital. These abdominal CT 
images demonstrated mild hepatomegaly with decreased 
attenuation on the precontrast phase images (Fig. 1A). The 
arterial phase images revealed heterogeneous enhancement 
of the liver with low-density lesions in the periportal areas 
(Fig. 1B). Ascites was also observed. The portal phase scan 
images showed homogeneous enhancement of the liver 
with focal hypoattenuating areas (Fig. 1C). These findings 
may be consistent with amyloidosis of the liver. Diffuse 
decreased splenic attenuation with contrast enhancement 
could be seen on the CT scans, but the size and shape 
of the spleen were within normal limits. The magnetic 
resonance cholangiopancreatographic images taken outside 
our hospital showed no evidence of biliary obstruction.
PET/CT using a Discovery STe scanner (GE Healthcare, 
Milwaukee, WI) was performed to rule out the possibility of 
a hidden malignancy. The patient fasted for six hours before 
scanning. Before injection, the patient’s glucose levels were 
within the normal range. One hour after injection of 
18F-FDG 
(5.5 MBq/kg), a non-contrast CT scan and subsequent 
emission scan (2.5 min/bed, 3D mode) were obtained from 
the mid femur to the base of the skull. The attenuation-
corrected PET images were reconstructed with a 3D iterative 
ordered subsets expectation maximization algorithm (2 
iterations, 20 subsets). In the final step, a 3D isotropic 
Gauss filter was applied for a final image resolution of 4.29 
mm full width at half maximum.
The maximum intensity projection and transverse fusion 
PET/CT images revealed marked diffusely increased 
18F-FDG 
uptake in the enlarged liver with a maximum standardized 
uptake value (SUVmax) of 7.2 (Fig. 1D, E). The average 
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Fig. 1. Abdominal CT and PET/CT image of 64-year-old female patient with primary AL hepatic 
amyloidosis.
A. Precontrast phase scan shows mild hepatomegaly with decreased attenuation of liver (attenuation 
value of hepatic parenchyma is 44 HU). B. Arterial phase scan shows heterogeneous enhancement 
with low-density lesions in periportal areas (arrows). C. Portal phase CT scan shows homogeneous 
enhancement of liver (91 HU) with focal hypoattenuating areas (78 HU) (arrow). D, E. Maximum intensity 
projection (D) and transverse fusion 
18F-FDG PET/CT images (E) of primary AL hepatic amyloidosis 
patient. There was marked diffusely increased 
18F-FDG uptake in enlarged liver (SUVmax = 7.2, SUVave = 4.1). 
In addition, high 
18F-FDG uptake in bilateral adrenal glands was observed without mass, which suggested 
benign hyperplasia.Korean J Radiol 12(5), Sep/Oct 2011 kjronline.org 636
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hepatic SUV (SUVave) was measured on three contiguous 
transverse slices at the hepatic hilum using a cut-off SUV 
of 1.8 for boundary determination (derived from the blood 
pool activity of the aortic arch), which resulted in a value 
of 4.1. Other findings on the PET/CT images included 
high 
18F-FDG uptake (SUVmax, right:left = 10.9:14.6) in the 
bilateral adrenal glands without a definite mass seen on 
the non-contrast CT images that would suggest benign 
lesion. However, the spleen and bone marrow did not show 
increased 
18F-FDG uptake, and the size of spleen was within 
the normal limit.
On the 2nd admission day, a percutaneous ultrasound-
guided biopsy targeting the right hepatic lobe was 
performed. The obtained liver specimen stained positive 
with Congo red. There were irregularly expanded portal 
triads infiltrated with an amorphous eosinophilic material, 
and diffuse amyloid (AL type) deposition had replaced 
most of the normal liver tissue, which is all consistent 
with amyloidosis (Fig. 1F, G). On the 7th admission day, 
the patient’s blood creatinine level increased (1.34 mg/
dL) and she developed anuria. On the 8th day, bone marrow 
biopsy was performed due to detecting serum monoclonal 
gammopathy. This led to the definitive diagnosis of multiple 
myeloma through the demonstration of a 35% plasma cell 
population and the presence of kappa light chain-restricted 
monoclonal plasma cells. The patient then suffered gradual 
progression of the hepatic coma, and she subsequently 
underwent liver transplantation, followed by hepatic artery 
revision and a 2nd liver transplantation due to hepatic 
artery occlusion. The patient finally died of hepatic failure 
with sepsis on the 29th admission day.
DISCUSSION
Amyloidosis is an uncommon disease that is characterized 
by abnormal extracellular deposition and accumulation 
of protein and protein derivatives. Primary amyloidosis 
(AL-amyloidosis), in which the amyloid deposition is 
derived from the light chain fragment of immunoglobulin, 
constitutes a wide spectrum of monoclonal gammopathies 
that includes multiple myeloma, Waldenstrom’s 
macroglobulinemia, heavy chain disease and monoclonal 
gammopathies of unknown significance (8). Approximately 
12-15% of the patients with multiple myeloma develop 
systemic amyloidosis during the course of disease, and up 
to 30% of patients have subclinical amyloid deposits (9). 
Hepatic involvement is common in systemic amyloidosis 
and in patients with B-cell and plasma cell dyscrasia. 
However, hepatic amyloidosis generally presents as 
hepatomegaly and minimally abnormal liver function test 
findings, while it rarely causes symptoms from deteriorated 
liver function (4). Jaundice, for instance, occurs in only 5% 
of the patients with hepatic amyloidosis (3). Furthermore, 
serious symptoms such as fatal hepatic failure are extremely 
rare in patients with multiple myeloma-associated 
amyloidosis (3-5).
Fig. 1. Abdominal CT and PET/CT image of 64-year-old female patient with primary AL hepatic amyloidosis.
F, G. In Biopsy specimens, there was amorphous eosinophilic material in liver parenchyma (F, Hematoxylin & Eosin staining, x 100), which was 
stained orange-red by Congo red (G, x 200), and this was consistent with amyloidosis.
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The findings of hepatic amyloidosis on ultrasound (US), 
CT or magnetic resonance imaging (MRI) are generally 
non-specific. The ultrasound exams of patients with 
hepatic amyloidosis display such non-specific findings 
as heterogeneous echogenicity and diffuse decreased 
parenchymal echogenicity (10). The findings on contrast-
enhanced CT are also non-specific, including diffuse or 
focal hypoattenuating areas in the liver with or without 
extensive calcification (11). Similar diffuse hypoattenuated 
liver parenchyma was reported in a case with multiple 
myeloma-associated amyloidosis in a patient with hepatic 
failure (3). The presence of asymmetric and triangular 
hepatomegaly with the apex at the falciform ligament is 
a characteristic feature of hepatic amyloidosis, which may 
help its differentiation from other infiltrative diseases 
(10). In our patient, the portal phase CT demonstrated 
mild hepatomegaly with heterogeneous enhancement and 
low-density lesions in the periportal areas. MRI of hepatic 
amyloidosis has been reported to show increased signal 
intensity of the hepatic parenchyma on the T1-weighted 
images without a signal change on the T2-weighted images 
(12).
There have been several case studies reporting the 
accumulation of pentavalent or trivalent technetium-99m-
labeled dimercaptosuccinic acid (
99mTc-DMSA) in amyloidosis 
associated with multiple myeloma, which is unique in that 
the increased splenic uptake significantly contributed to 
reaching the final diagnosis (13, 14). However, there have 
been no reports regarding 
99mTc-DMSA scanning in a patient 
with hepatic amyloidosis. In patients with pulmonary 
amyloidosis, increased 
18F-FDG uptake has been shown in 
the multiple pulmonary nodules (6). In our patient, PET/CT 
revealed markedly diffusely increased 
18F-FDG uptake in the 
enlarged liver. The laboratory results were not consistent 
with hepatitis at the time of PET/CT, whereas staining 
of hepatic tissue confirmed the presence of amyloidosis. 
Considering those results, markedly diffusely increased 
18F-FDG uptake in the liver may be a PET/CT finding of 
hepatic amyloidosis.
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